First Postpartum Depression Pill, Research Led by Northwell Health’s Feinstein Institutes
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved the first at-home oral pill, zuranolone, which will be sold under the brand named Zurzuvae, for treating perinatal or postpartum depression (PPD) – a condition one in eight birthing women experience.